Analyst Gil Blum Reaffirms Confidence in Autolus Therapeutics with Buy Rating and Unchanged Price Target
December 2, 2023: In a recent evaluation, Gil Blum, the esteemed Needham analyst, has once again expressed his unwavering confidence ...
Tag: AUTL
Autolus Therapeutics plc (NASDAQ:AUTL) Shows Decrease in Short Interest and Positive Outlook from Analysts
Autolus Therapeutics plc (NASDAQ:AUTL) experienced a significant decrease in short interest during the month of August, according to the latest ...
ProShare Advisors LLC Increases Holdings in Fidelity National Information Services, Inc.
In its most recent Form 13F filing with the Securities and Exchange Commission (SEC), ProShare Advisors LLC has reported an ...
Public Sector Pension Investment Board Increases Stake in The Beauty Health Company, Reflecting Growing Confidence in Investment Potential
Public Sector Pension Investment Board has significantly increased its stake in The Beauty Health Company during the first quarter of ...
ExodusPoint Capital Management LP Increases Stake in Autolus Therapeutics plc: Boosting Confidence in T Cell Therapies for Cancer Treatment
ExodusPoint Capital Management LP has recently increased its stake in Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in the ...
Promising Results of AUTO122 Phase 1 Study in Pediatric Bcell Acute Lymphoblastic Leukemia Published in Blood
On September 5, 2023, Autolus Therapeutics made an exciting announcement regarding the publication of data from the AUTO1/22 Phase 1 ...
Autolus Therapeutics plc: Decline in Short Interest and Growing Analyst Attention
Autolus Therapeutics plc (NASDAQ:AUTL) experienced a significant decline in short interest during the month of August, according to recent data. ...
MAI Capital Management Reduces Stake in Autolus Therapeutics: a Strategic Move in Portfolio Management
August 22, 2023 - MAI Capital Management, a renowned institutional investor, has recently reported a reduction in its stake in ...
Autolus Therapeutics’ Stock Price Rises Following Truist Financial’s Increased Price Target
Autolus Therapeutics plc (NASDAQ:AUTL) experienced a 3.1% increase in its share price during mid-day trading on Friday, following Truist Financial's ...
ObeCel Revolutionizing CART Therapy for Adult ALL
Autolus Therapeutics' groundbreaking therapy, Obe-Cel, is revolutionizing the field of CD19 CAR T cell treatments. Unlike its predecessors, Obe-Cel addresses ...